Longeveron Inc. Common Stock (LGVN)

Price$0.73

Value ScoreC

Growth ScoreD

Momentum ScoreB

Favorite Metrics

Price vs S&P 500 (26W)2.06%

Price vs S&P 500 (4W)-13.62%

VGM Score46.27

Market Capitalization$23.09M

All Metrics

Book Value / Share (Quarterly)$0.52

P/TBV (Annual)3.18x

Indicated Dividend (Annual)$0.00

Revenue Growth (3Y)-0.63%

Cash Flow / Share (Quarterly)$-0.61

Price vs S&P 500 (YTD)36.11%

Gross Margin (TTM)65.13%

Net Profit Margin (TTM)-1844.49%

EPS (TTM)$-1.17

10-Day Avg Trading Volume0.29M

EPS Excl Extra (TTM)$-1.17

Revenue Growth (5Y)-26.60%

EPS (Annual)$-1.29

ROI (Annual)-400.07%

Gross Margin (Annual)66.97%

Net Profit Margin (5Y Avg)-1685.60%

Cash / Share (Quarterly)$0.51

Revenue Growth QoQ (YoY)4.46%

ROA (Last FY)-221.26%

Revenue Growth TTM (YoY)-45.35%

EBITD / Share (TTM)$-1.09

ROE (5Y Avg)-185.61%

Operating Margin (TTM)-1881.66%

Cash Flow / Share (Annual)$-0.84

P/B Ratio1.44x

P/B Ratio (Quarterly)1.90x

Net Income / Employee (Annual)$-873,200

EV / Revenue (TTM)6.03x

Net Interest Coverage (TTM)-4260.25x

ROA (TTM)-140.67%

EPS Incl Extra (Annual)$-1.29

Current Ratio (Annual)1.33x

Quick Ratio (Quarterly)3.64x

3-Month Avg Trading Volume3.97M

52-Week Price Return-38.14%

Revenue / Employee (TTM)$46,800

Tangible BV / Share (Quarterly)$0.45

P/S Ratio (Annual)19.26x

Asset Turnover (Annual)0.12x

52-Week High$1.80

Operating Margin (5Y Avg)-1686.28%

EPS Excl Extra (Annual)$-1.29

CapEx CAGR (5Y)17.87%

26-Week Price Return9.99%

Quick Ratio (Annual)1.17x

13-Week Price Return47.21%

Total Debt / Equity (Annual)0.00x

Current Ratio (Quarterly)3.88x

Enterprise Value$7.33M

Revenue / Share Growth (5Y)-53.11%

Asset Turnover (TTM)0.08x

Revenue / Employee (Annual)$46,100

Pretax Margin (Annual)-1893.58%

Cash / Share (Annual)$0.20

3-Month Return Std Dev163.80%

Gross Margin (5Y Avg)52.55%

Net Income / Employee (TTM)$-862,700

ROE (Last FY)-400.07%

Net Interest Coverage (Annual)-73.31x

EPS Basic Excl Extra (Annual)$-1.29

Receivables Turnover (TTM)25.07x

Total Debt / Equity (Quarterly)0.00x

EPS Incl Extra (TTM)$-1.17

Receivables Turnover (Annual)12.76x

ROI (TTM)-202.41%

P/S Ratio (TTM)18.99x

Pretax Margin (5Y Avg)-1685.60%

Revenue / Share (Annual)$0.07

Tangible BV / Share (Annual)$0.15

Price vs S&P 500 (52W)-62.50%

Year-to-Date Return44.27%

5-Day Price Return-5.19%

EPS Normalized (Annual)$-1.29

ROA (5Y Avg)-113.92%

Net Profit Margin (Annual)-1893.58%

Month-to-Date Return-5.46%

Cash Flow / Share (TTM)$-0.89

EBITD / Share (Annual)$-1.26

Operating Margin (Annual)-1942.20%

LT Debt / Equity (Annual)0.00x

ROI (5Y Avg)-185.61%

LT Debt / Equity (Quarterly)0.00x

EPS Basic Excl Extra (TTM)$-1.17

P/TBV (Quarterly)2.21x

P/B Ratio (Annual)1.90x

Pretax Margin (TTM)-1844.49%

Book Value / Share (Annual)$0.25

Price vs S&P 500 (13W)38.95%

Beta-0.31x

Revenue / Share (TTM)$0.05

ROE (TTM)-202.41%

52-Week Low$0.47

vGradeC

gGradeD

mGradeB

vgmGradeC

Show chart for

Earnings Surprise History

Q1 26-0.19est. -0.17

Analyst Recommendations

Feb 2026

Mar 2026

Apr 2026

May 2026

4.13

Industry Peers — Pharmaceuticals(550)

Symbol	Value Score	Growth Score	Momentum Score	Price
LGVNLongeveron Inc. Common Stock	C	D	B	$0.73
LLYEli Lilly & Co.	D	B	B	$1131.42
JNJJohnson & Johnson	D	C	B	$232.77
ABBVABBVIE INC.	D	C	C	$227.23
MRKMerck & Co., Inc.	C	C	B	$120.79
NVSNovartis AG	C	C	C	$149.16
AZNAstraZeneca PLC	D	B	C	$185.95
NVONovo-Nordisk A/S	B	B	B	$42.96
ABTAbbott Laboratories	C	C	D	$91.07
PFEPfizer Inc.	B	C	C	$26.04
BMYBristol-Myers Squibb Co.	B	C	B	$57.27

About

Longeveron Inc is a clinical-stage biotechnology company developing Lomecel-B, an allogeneic stem cell therapy designed to promote tissue repair and regeneration in aging-related and life-threatening diseases. The company is advancing three pipeline programs targeting Hypoplastic Left Heart Syndrome, Alzheimer's disease, and aging-related frailty.